Protagonist Therapeutics (PTGX) – Investment Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Protagonist Therapeutics (NASDAQ: PTGX):

• 5/9/2026 – Protagonist Therapeutics was upgraded by Wall Street Zen from “hold” to “strong-buy”.
• 5/6/2026 – Protagonist Therapeutics had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $110.00 price target on the stock.
• 5/6/2026 – Protagonist Therapeutics had its “outperform” rating reaffirmed by Citigroup Inc..
• 5/6/2026 – Protagonist Therapeutics had its price target raised by Citizens Jmp from $120.00 to $137.00. They now have a “market outperform” rating on the stock.
• 5/6/2026 – Protagonist Therapeutics had its price target raised by Wedbush from $112.00 to $118.00. They now have an “outperform” rating on the stock.
• 4/14/2026 – Protagonist Therapeutics had its price target raised by Truist Financial Corporation from $110.00 to $121.00. They now have a “buy” rating on the stock.
• 3/19/2026 – Protagonist Therapeutics had its price target raised by Leerink Partners from $107.00 to $110.00. They now have an “outperform” rating on the stock.
• 3/19/2026 – Protagonist Therapeutics had its price target raised by JPMorgan Chase & Co. from $95.00 to $106.00. They now have an “overweight” rating on the stock.
• 3/19/2026 – Protagonist Therapeutics had its price target raised by Citigroup Inc. from $115.00 to $125.00. They now have a “buy” rating on the stock.
• 3/19/2026 – Protagonist Therapeutics had its price target raised by Barclays PLC from $113.00 to $119.00. They now have an “overweight” rating on the stock.
• 3/18/2026 – Protagonist Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $121.00 price target on the stock.
• 3/18/2026 – Protagonist Therapeutics had its “buy” rating reaffirmed by Johnson Rice.

Insider Buying and Selling

In other Protagonist Therapeutics news, Director Harold E. Selick sold 24,000 shares of the stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $105.00, for a total transaction of $2,520,000.00. Following the completion of the transaction, the director owned 60,845 shares of the company’s stock, valued at $6,388,725. This trade represents a 28.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Asif Ali sold 24,765 shares of Protagonist Therapeutics stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $104.24, for a total transaction of $2,581,503.60. Following the sale, the chief financial officer owned 60,753 shares of the company’s stock, valued at approximately $6,332,892.72. This represents a 28.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 272,345 shares of company stock valued at $27,294,066 over the last three months. Company insiders own 5.19% of the company’s stock.

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.